home / stock / jspr / jspr quote
Last: | $22.21 |
---|---|
Change Percent: | 0.0% |
Open: | $22.92 |
Close: | $22.21 |
High: | $23.99 |
Low: | $22.19 |
Volume: | 86,634 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$22.21 | $22.92 | $22.21 | $23.99 | $22.19 | 86,634 | 07-04-2024 |
$22.21 | $22.92 | $22.21 | $23.99 | $22.19 | 86,631 | 07-03-2024 |
$22.78 | $22.81 | $22.78 | $23.8349 | $22.725 | 95,710 | 07-02-2024 |
$23.14 | $22.45 | $23.14 | $23.59 | $21.525 | 95,895 | 07-01-2024 |
$22.7 | $21.89 | $22.7 | $23.49 | $20.97 | 1,613,520 | 06-28-2024 |
$22.01 | $22.49 | $22.01 | $22.96 | $20.98 | 159,030 | 06-27-2024 |
$20.98 | $21.05 | $20.98 | $21.05 | $19.11 | 142,252 | 06-26-2024 |
$21.3 | $22.42 | $21.3 | $23.09 | $21.2 | 85,062 | 06-25-2024 |
$22.5 | $22.16 | $22.5 | $22.605 | $21.89 | 79,557 | 06-24-2024 |
$22.12 | $22 | $22.12 | $22.21 | $21.47 | 76,310 | 06-21-2024 |
$21.86 | $22.99 | $21.86 | $23.18 | $20.5 | 122,850 | 06-20-2024 |
$23.19 | $24.3 | $23.19 | $24.64 | $22.81 | 190,097 | 06-19-2024 |
$23.19 | $24.3 | $23.19 | $24.64 | $22.81 | 190,097 | 06-18-2024 |
$24.32 | $24.87 | $24.32 | $25.03 | $24.05 | 64,101 | 06-17-2024 |
$25.02 | $24.4 | $25.02 | $25.245 | $23.9 | 72,416 | 06-14-2024 |
$24.34 | $23.99 | $24.34 | $24.98 | $23.7813 | 65,280 | 06-13-2024 |
$24 | $24.27 | $24 | $25.4 | $23.945 | 104,554 | 06-12-2024 |
$23.99 | $23.72 | $23.99 | $24.14 | $23.36 | 99,740 | 06-11-2024 |
$23.95 | $24.41 | $23.95 | $24.41 | $23.53 | 83,078 | 06-10-2024 |
$24.52 | $25.01 | $24.52 | $25.325 | $23.62 | 116,725 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Jasper Therapeutics Inc. Company Name:
JSPR Stock Symbol:
NASDAQ Market:
Jasper Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneou...
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CS...
2024-06-16 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...